# EDGAR Filing Document

**Accession Number:** 0001861657
**File Stem:** 0001641172-25-026620
**Filing Date:** 2025-9
**Character Count:** 7303
**Document Hash:** ca7d460478fff747d675ac9b2acd87dc
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001641172-25-026620.hdr.sgml**: 20250905

**ACCESSION NUMBER**: 0001641172-25-026620

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 13

**CONFORMED PERIOD OF REPORT**: 20250905

**ITEM INFORMATION**: Other Events

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20250905

**DATE AS OF CHANGE**: 20250904

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Tharimmune, Inc.
- **CENTRAL INDEX KEY:** 0001861657
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 842642541
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-41210
- **FILM NUMBER:** 251294851

**BUSINESS ADDRESS:**
- **STREET 1:** 1200 ROUTE 22 EAST
- **CITY:** BRIDGEWATER
- **STATE:** NJ
- **ZIP:** 08807
- **BUSINESS PHONE:** 302-743-2995

**MAIL ADDRESS:**
- **STREET 1:** 245 MAIN STREET
- **STREET 2:** SUITE 204
- **CITY:** CHESTER
- **STATE:** NJ
- **ZIP:** 07930

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Tharimmune, Inc
- **DATE OF NAME CHANGE:** 20230925

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Hillstream BioPharma Inc.
- **DATE OF NAME CHANGE:** 20210511

?xml version='1.0' encoding='ASCII'?

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the**

**Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported) **September 5, 2025**

**THARIMMUNE, INC.**

(Exact name of registrant as specified in its charter)

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-41210** | **84-2642541** |
| (State or other jurisdiction<br> of incorporation) | (Commission<br> File Number) | (I. R. S. Employer<br> Identification No.) |

---

**34 Shrewsbury Avenue, Suite 1C**

**Red Bank, NJ 07701**

(Address of principal executive offices, including zip code)

**(732) 889-3111**

(Registrant's telephone number, including area code)

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading Symbol(s)** | **Name of each exchange on which registered** |
| Common stock, $0.0001 par value | THAR | The Nasdaq Stock Market LLC |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

**Item 8.01 Other Events.**

On April 1, 2025, Tharimmune, Inc. (the "Company") received a notice (the "Notice") from the Listing Qualifications staff of Nasdaq notifying the Company that its stockholders equity as reported in its Annual Report on Form 10-K for the period ended December 31, 2024, did not satisfy the continued listing requirements under Nasdaq Listing Rule 5550(b)(1) for The Nasdaq Capital Market, which requires that a listed company's stockholder equity be at least $2,500,000. On May 15, 2025, the Company submitted its plan of compliance to Nasdaq.

On July 25, 2025, the Company closed on a registered direct offering of shares of common stock (and common stock equivalents) and a concurrent private placement of warrants for gross proceeds of approximately $1.7 million. In addition, on August 27, 2025, the Company closed on a registered direct offering of shares of common stock (and common stock equivalents) for gross proceeds of approximately $5.35 million.

As a result of the transactions described above, as of the date hereof, the Company's stockholders equity is greater than $2,500,000. For more information, please refer to the Company's unaudited consolidated balance sheet as of August 31, 2025 which has been furnished as Exhibit 99.1 to this Form 8-K.

**Item 9.01 Financial Statements and Exhibits.** 

(d) <u>Exhibits</u>

---

| | |
|:---|:---|
| **Exhibit No.** | **Description** |
| 99.1 | [Unaudited Consolidated Balance Sheet as of August 31, 2025](ex99-1.htm) |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | |
|:---|:---|
| Date: September 5, 2025 | **Tharimmune, Inc.** |
|  | */s/ Sireesh Appajosyula* |
|  | Sireesh Appajosyula |
|  | Chief Executive Officer |

---

## Exhibit 99.1

**Exhibit 99.1**

**THARIMMUNE, INC.**

**CONDENSED CONSOLIDATED BALANCE SHEETS**

---

| | |
|:---|:---|
|  | August 31, 2025 |
|  | (Unaudited) |
| **ASSETS** |  |
| Current assets |  |
| &nbsp;&nbsp;&nbsp;Cash and cash equivalents | $8782667 |
| &nbsp;&nbsp;&nbsp;Prepaid expenses and other current assets | 151591 |
| &nbsp;&nbsp;&nbsp;Deferred offering costs | 92168 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total current assets | 9026426 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total assets | $9026426 |
| **LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)** |  |
| Current liabilities |  |
| &nbsp;&nbsp;&nbsp;Accounts payable | $870296 |
| &nbsp;&nbsp;&nbsp;Accrued expenses | 1046057 |
| &nbsp;&nbsp;&nbsp;Insurance premium financing liability | 49599 |
| &nbsp;&nbsp;&nbsp;Note payable | 184139 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total current liabilities | 2150091 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total liabilities | 2150091 |
| Stockholders' equity |  |
| &nbsp;&nbsp;&nbsp;Preferred stock, $0.0001 par value, 10,000,000 shares authorized, no shares issued and outstanding as of August 31, 2025 |  |
| &nbsp;&nbsp;&nbsp;Common stock, $0.0001 par value, 250,000,000 shares authorized, 6,809,460 shares issued and 6,809,214 shares outstanding as of August 31, 2025, respectively | 681 |
| &nbsp;&nbsp;&nbsp;Additional paid-in capital | 49095404 |
| &nbsp;&nbsp;&nbsp;Accumulated deficit | (42149785) |
| &nbsp;&nbsp;&nbsp;Treasury stock, at cost, 246 shares held in treasury as of August 31, 2025 | (69965) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total stockholders' equity | 6876335 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total liabilities and stockholders' equity | $9026426 |

---